Bullous pemphigoid followed by pustular psoriasis showing Th1, Th2, Treg and Th17 immunological changes. 2009

Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
Department of Dermatology, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.

Psoriasis vulgaris is occasionally accompanied by autoimmune bullous diseases, but the opposite is very rare. We document here the first reported case of generalized pustular psoriasis that appeared during steroid therapy for bullous pemphigoid. The serum cytokine levels and the results of an immunohistochemical study over the disease course suggest that the immunological state was consistent with a shift from Th2-dominance to Th1-dominance. IL-17-producing cells appeared in the skin lesions when each disease was most exacerbated and disappeared after remission. Thus, the present case demonstrated a dynamic immunological state in which the appearances of Th1 and Th2 as well as Th17 varied during the course of the disease.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D010391 Pemphigoid, Bullous A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis. Pemphigoid,Bullous Pemphigoid,Pemphigoids
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006377 T-Lymphocytes, Helper-Inducer Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions. Helper Cell,Helper Cells,Helper T Cell,Helper-Inducer T-Lymphocytes,Inducer Cell,Inducer Cells,T-Cells, Helper-Inducer,T-Lymphocytes, Helper,T-Lymphocytes, Inducer,Helper T-Cells,Cell, Helper T,Cells, Helper T,Helper Inducer T Lymphocytes,Helper T Cells,Helper T-Cell,Helper T-Lymphocyte,Helper T-Lymphocytes,Helper-Inducer T-Cell,Helper-Inducer T-Cells,Helper-Inducer T-Lymphocyte,Inducer T-Lymphocyte,Inducer T-Lymphocytes,T Cell, Helper,T Cells, Helper,T Cells, Helper Inducer,T Lymphocytes, Helper,T Lymphocytes, Helper Inducer,T Lymphocytes, Inducer,T-Cell, Helper,T-Cell, Helper-Inducer,T-Cells, Helper,T-Lymphocyte, Helper,T-Lymphocyte, Helper-Inducer,T-Lymphocyte, Inducer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001623 Betamethasone A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724) Betadexamethasone,Flubenisolone,Celeston,Celestona,Celestone,Cellestoderm

Related Publications

Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
March 2019, International journal of dermatology,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
May 2024, International archives of allergy and immunology,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
January 1996, The British journal of dermatology,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
October 1998, The British journal of dermatology,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
June 2022, Journal of periodontal research,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
October 2021, European journal of dermatology : EJD,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
January 2019, In vivo (Athens, Greece),
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
November 2002, Journal of dermatological science,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
January 2008, Chemical immunology and allergy,
Shinsuke Yasukawa, and Teruki Dainichi, and Hisashi Kokuba, and Yoichi Moroi, and Kazunori Urabe, and Takashi Hashimoto, and Masutaka Furue
May 2018, Medical science monitor : international medical journal of experimental and clinical research,
Copied contents to your clipboard!